2023 World Conference on Lung Cancer (Posters)-P2.02. Neoadjuvant Immunotherapy Related Pneumonitis in Non-Small Cell Lung Cancer Patients: Incidence, Risk Factors, and Management

P2.02. Neoadjuvant Immunotherapy Related Pneumonitis in Non-Small Cell Lung Cancer Patients: Incidence, Risk Factors, and Management - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the incidence, clinical characteristics, and management of checkpoint inhibitor pneumonitis (CIP) in non-small cell lung cancer (NSCLC) patients undergoing neoadjuvant immunotherapy. The study analyzed the medical records of 97 NSCLC patients who received neoadjuvant CPI therapy between December 2018 and May 2022. Of these patients, 24.7% developed CIP. The median time to onset of CIP symptoms was 8.5 weeks after therapy initiation. Most cases of CIP were mild to moderate in severity and managed with corticosteroids. Patients with CIP had a longer duration of immunotherapy and a higher baseline C-reactive protein level compared to those without CIP. Only 20.8% of patients with CIP required systemic corticosteroid therapy, and 8.3% developed severe respiratory failure requiring mechanical ventilation. No deaths were attributed to respiratory failure. The study highlights the importance of close monitoring for CIP and prompt recognition and management of symptoms in NSCLC patients receiving checkpoint inhibitors. Further studies are needed to identify risk factors and optimize the management of CIP in this patient population.

Asset Subtitle

Long Jiang

Meta Tag

Speaker Long Jiang

Topic Local-Regional NSCLC: Toxicities of Multimodality Therapy

Keywords

checkpoint inhibitor pneumonitis

non-small cell lung cancer

neoadjuvant immunotherapy

incidence

clinical characteristics

management

medical records

C-reactive protein level

systemic corticosteroid therapy

respiratory failure